VENLOR
Chronic Disease
University of WashingtonSmall moleculeN/ADormant
D
30/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 15/ 100
- Competitive Position
- 95/ 100
Competitive context
7 Active assets in the Chronic Disease cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Velaglucerase Alfa Shaare Zedek Medical Center | Phase 4 | BB |
(±)-2-(O-CHLOROPHENYL)-2-(METHYLAMINO)CYCLOHEXANONE RIVER Foundation | Phase 4 | BB |
NEPENTHE Federal University of Paraíba | Phase 4 | BB |
Asenapine Centre de Recherche de l'Institut Universitaire en Santé Mentale de Québec | Phase 4 | BB |
Naltrexone Pfizer | Phase 4 | BB |
View all 39 →
Same molecule, other indications
VENLOR is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →